Company intelligence / Profile preview
LIB Therapeutics
Cincinnati, Ohio, United Stateslibtherapeutics.com ↗
- Ownership
- Private
- Development stage
- NDA
01
Overview
LIB Therapeutics has submitted a Biologics License Application (BLA) to the FDA for Lerodalcibep, with a PDUFA date of December 12, 2025. The drug has demonstrated robust and sustained long-term LDL cholesterol-lowering in clinical trials, enabling the majority of patients to achieve lower LDL-cholesterol targets.
- Therapeutic areas
- Cardiovascular
- Modalities
- Protein-based therapeuticsAdnectin-based fusion proteins
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Hasten Biopharmaceuticals Co, Ltd. (for development and commercialization in Greater China)
Beyond the preview
Go deeper on LIB Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LIB Therapeutics.